Fragile X syndrome (FXS) is a common form of inherited intellectual disability and is one of the leading known causes of autism. The mutation responsible for FXS is a large expansion of the trinucleotide CGG repeat in the 5 untranslated region of the X-linked gene FMR1. This expansion leads to DNA methylation of FMR1 and to transcriptional silencing, which results in the absence of the gene product, FMRP, a selective messenger RNA (mRNA)-binding protein that regulates the translation of a subset of dendritic mRNAs. FMRP is critical for mGluR (metabotropic glutamate receptor)-dependent long-term depression, as well as for other forms of synaptic plasticity; its absence causes excessive and persistent protein synthesis in postsynaptic dendrites and dysregulated synaptic function. Studies continue to refine our understanding of FMRP's role in synaptic plasticity and to uncover new functions of this protein, which have illuminated therapeutic approaches for FXS.
INTRODUCTION
Clinical diagnoses of common complex disorders, such as Alzheimer's disease and autism, inevitably encompass heterogeneous subsets of patients with differing molecular mechanisms of disease. The study of rare Mendelian forms of the broader disease makes it possible to identify a homogeneous group of patients, thereby simplifying molecular analysis. Focusing on the molecular genetics of these single-gene disorders has proven valuable in identifying the underlying molecular pathways of disease, the knowledge of which can then be applied to our general understanding of the broader nonMendelian forms. This pattern is especially evident in the study of intellectual disability (ID) and autism by the knowledge gained of fragile X syndrome (FXS).
Inherited ID comprises a broad, heterogeneous group of disorders; with an incidence of 1 in 5,000 males (1), FXS represents one of the most common forms of inherited ID. Since the underlying gene was cloned 20 years Eighteen-year-old male with fragile X syndrome.
ago, there has been tremendous progress in our understanding of the neurological deficits that contribute to FXS. As expected, research into FXS has revealed many of the pathways that are critical to learning and memory formation. Knowledge of these pathways has enabled the rational design of potential therapeutics for FXS. Additionally, it has opened new avenues of investigation into the molecular mechanisms behind other forms of ID and autism.
Identification of Fragile X Syndrome as a Distinct Syndrome
In 1969, Lubs (2) identified a family with four male members diagnosed with ID, each of whom had an unusual chromosomal gap on his X chromosome long arm. This observation had limited clinical utility until 1977, when Sutherland (3) showed that specific culture conditions were necessary to visualize the gap consistently. Such chromosomal gaps or constrictions in metaphase spreads are termed fragile sites due to their propensity to break under certain conditions (4) . It soon became clear that this cytogenetic marker is diagnostic for a distinct X-linked form of ID, designated FXS after the fragile site found in patients.
Individuals with FXS have mild to severe ID, often with autism-like behaviors (5) . Other neurological symptoms include developmental delay and increased susceptibility to seizures (5) . Upon postmortem examination, the neurons of FXS patients are found to have dense, immature dendritic spines (5) . The most prominent physical symptom in males is macroorchidism, which usually develops just before puberty (5) . More subtle physical symptoms may include a long, narrow face with prominent ears, joint laxity, and flat feet (Figure 1 ) (5) . These features point to a potential connective tissue disorder that has yet to be elucidated in any detail.
Analysis of more FXS pedigrees showed that the syndrome does not follow a typical pattern of inheritance for an X-linked disease. Most prominently, the pedigrees contained male obligate carriers with no symptoms of FXS (6, 7). Furthermore, the grandchildren of these Untranslated regions (UTRs): the 5 and 3 segments of messenger RNA, which are not translated into protein healthy male carriers developed FXS at much higher rates than did the siblings of the carriers (6). This example of genetic anticipation, named the Sherman paradox, remained a mystery until the mutation underlying FXS was identified.
Identification of the FMR1 Gene
The gene for FXS was cloned in 1991 and named fragile X mental retardation gene 1 (FMR1) (8). FMR1 is located at cytogenetic position Xq27.3, the exact location of the diagnostic fragile site (9). In almost all cases, the causative mutation is the expansion of a CGG repeat located in the 5 untranslated region (UTR) of FMR1. Although this was a novel mutational mechanism at the time of its discovery, such trinucleotide-repeat expansions have since been found in other disease genes (see the sidebar). In FMR1, the length of the CGG repeat is polymorphic in the healthy population and ranges from 6 to 54 repeats (Figure 2a ) (10) . When the number of repeats exceeds 200, the expansion is referred to as a full mutation allele and results in FXS (10). At the molecular level, the large number of CGG repeats in the full mutation leads to marked methylation of both the CGG repeats and the FMR1 promoter, hypoacetylation of associated histones, and chromatin condensation; these epigenetic changes result in transcriptional silencing of FMR1 and subsequent loss of its protein product, fragile X mental retardation protein (FMRP) (Figure 2c ) (11) (12) (13) (14) . Alleles with an intermediate number (55-200) of repeats are referred to as premutation alleles (10). Premutation alleles do not cause an FXS phenotype (see the section titled Premutation Allele Phenotypes, below) but are prone to large increases in repeat length during meiosis, especially female meiosis (10). The observation that premutation alleles are more vulnerable to expansion during meiosis also helped resolve the Sherman paradox; we now understand that males with a premutation allele transmit it intact to their healthy daughters (10). Such premutation alleles in the daughters often expand to full mutation alleles during
TRINUCLEOTIDE REPEAT EXPANSIONS AND HUMAN DISEASE
Trinucleotide repeat (TNR) expansions are the causal mutation in approximately 20 disorders in addition to FXS, including Huntington disease, myotonic dystrophy, and several inherited ataxias (44). TNRs are stretches of DNA composed of a threebase sequence (i.e., CGG, CAG, CTG, and GAA) that is repeated multiple times in tandem. Repeats of certain trinucleotides tend to expand or contract; if this occurs during gametogenesis, a different number of repeats may be passed on to the next generation. The exact mechanisms of repeat instability are unknown; however, it is believed that during DNA replication and repair, the TNR tract forms a hairpin loop that is incorrectly incorporated into the genome by DNA polymerase (44). Because longer repeats are more unstable than short ones, TNR disorders often display genetic anticipation. TNRs may be located in either the coding region or the noncoding region of genes. When found in coding regions, TNRs produce proteins with extended polyamino acid stretches that affect many aspects of normal function, such as cleavage and aggregate formation. TNRs in the noncoding region, as in myotonic dystrophy and FXS, may lead to toxic RNA production or cause transcriptional silencing. oogenesis, which causes the higher incidence of FXS observed in the next generation (10).
It is now the standard of care to measure the FMR1 CGG repeat size in all children who present with developmental delay, ID, or autism (5) . Given the broad heterogeneity of such patients, typically only 1% to 3% of such children tested have the full mutation that leads to a diagnosis of FXS (15) . The full mutation is almost completely penetrant in males, but only 50% of females with a full mutation show FXS symptoms, probably because of random X inactivation. Although most known FXS cases are caused by the expansion of the CGG repeat to a full mutation, a small number of deletions and missense mutations in the FMR1 gene have also been reported (16) (17) (18) . Recent studies suggest that more comprehensive screening for such mutations may increase the diagnostic yield by 30% compared with screening for repeat length alone (17) . In particular, there remains an However, levels of FMRP are actually lower than in healthy individuals. Higher levels of FMR1 messenger RNA (mRNA) cause fragile X-associated tremor/ataxia syndrome (FXTAS) and fragile X-related primary ovarian insufficiency (FXPOI), probably because of the expanded CGG repeats in the mRNA that sequester certain mRNA-binding proteins. (c) Full mutation alleles (>200 repeats) lead to epigenetic changes in the CGG repeats and in the promoter of FMR1, as well as transcriptional silencing of the gene. Symptoms of fragile X syndrome (FXS) are caused by the lack of FMRP.
Primary ovarian insufficiency (POI):
the onset of menopause at or before the age of 40 unexplained deficit of FMR1 missense mutations; only two have been reported thus far (17, 18) .
Premutation Allele Phenotypes
Although premutation alleles do not cause FXS, they can lead to two other distinct disorders: fragile X-related primary ovarian insufficiency (FXPOI) and fragile X-associated tremor/ataxia syndrome (FXTAS). FXPOI affects approximately 20% of female premutation carriers (19) ; some of these women experience primary ovarian insufficiency as early as their teenage years. The number of CGG repeats correlates with the penetrance and age of onset, albeit in a nonlinear fashion (20) . There have also been conflicting reports concerning the presence of a paternal parent-of-origin effect in FXPOI (21) (22) (23) . Very little is known about the molecular mechanism behind FXPOI, although differing hormone levels may play a role (24, 25) .
FXTAS is a late-onset neurodegenerative disease that manifests as progressive-action tremor and ataxia; some cases also show progressive cognitive decline (26) . Postmortem examinations reveal ubiquitin-positive intranuclear inclusions throughout the neurons and astrocytes of FXTAS patients (27, 28) . Penetrance in male premutation carriers older than age 70 is greater than 50% (29) , whereas penetrance in females is lower (30) . Larger CGG repeats confer an increased risk of developing FXTAS (31) .
Investigations into the effect of the premutation allele on FMR1 processing have revealed much about the pathogenesis of FXTAS. Instead of being methylated and silencing transcription, as in the full mutation, CGG repeats in the premutation range lead to increased levels of FMR1 messenger RNA (mRNA) (32) (33) (34) ; however, FMRP levels are modestly lower than levels in normal individuals (Figure 2b ) (33) (34) (35) . The expanded CGG repeats cause FMR1 mRNA transcripts to form intranuclear aggregates that grow larger over time and probably correlate with the inclusions observed in FXTAS patients (36). The molecular basis for these observations is as yet unknown, although the presence of the expanded CGG repeat itself seems to be responsible (37, 38). Furthermore, several RNA-binding proteins, including Purα, CUGBP1, heterogeneous ribonucleoprotein (hnRNP) A2/B1, and Sam68, interact with CGG-repeat RNA (39-41) and may be involved in the formation of aggregates.
One hypothesis to explain the pathogenic effect of the premutation allele is that the expanded CGG repeats drive elevated FMR1 transcript levels, which then recruit RNAbinding proteins to intranuclear aggregates, thereby titrating the proteins away from their normal function in other cellular locations and leading to neurodegeneration. Remarkably, overexpression of Purα, hnRNP A2/B1, or CUGBP1 can rescue the neurodegenerative phenotype observed in the Drosophila melanogaster model of FXTAS (39, 40). Additional support for this hypothesis comes from the findings that Sam68 can be sequestered by CGG-repeat transcripts in cell culture (41) and that knockout (KO) of Sam68 as well as Purα in mice causes motor-coordination deficits (42, 43). These findings suggest that reduced levels of Sam68 and/or Purα may be responsible for some of the FXTAS phenotypes.
Animal Models and Stem Cells
FMR1 is highly conserved across species (8), which has allowed for the development of several animal models of FXS. The most widely used models have been generated in the mouse and fruit fly. The FMR1 ortholog in the mouse, Fmr1, is located on the murine X chromosome, and its amino acid sequence has 97% homology to FMRP (45). Unfortunately, there is no relevant animal model of the full CGG expansion, as mice engineered with an expanded number of repeats fail to recapitulate the methylation and transcriptional silencing found in humans (34) . However, a targeted deletion of exon 5 created a KO mouse lacking FMRP, the functional equivalent of the full mutation in humans (46). These mice recapitulate many of the phenotypes observed in FXS patients, including disrupted learning and memory, increased susceptibility to seizures, and large testes (46). They also show an abundance of dense, immature dendritic spines, as observed in FXS patients (47). More recently, a mouse line was engineered in which loxP sites flank the promoter and exon1 of Fmr1, which allowed for conditional KO of the gene (48). This latest mouse model will enable the creation of null alleles in specific cell types and at specific stages of development, thereby providing new ways to explore FMRP's function in vivo. Another mouse model was created in which one of the rare missense mutations observed in patients was introduced into the endogenous murine Fmr1 gene (49). These mice phenocopy the deficits observed in Fmr1 KO mice (49), thereby allowing a better understanding of the effects of this unusual mutation.
D Advances in embryonic and induced pluripotent stem (iPS) cell technology are also allowing investigations into aspects of FXS that are difficult to study in animal models. Most notably, both the timing and the mechanism behind the methylation and gene silencing observed in full mutation alleles remain poorly understood, and as noted above, mouse models using a CGG expansion cannot replicate the methylation or gene silencing found in humans (34) . Human embryonic stem cell lines derived from embryos diagnosed with a full mutation showed that FMR1 is unmethylated and expressed in these cells, but upon differentiation of the cells FMR1 undergoes methylation, histone modifications, and silencing (56). This finding is consistent with those from studies of human chorionic villi samples, which indicate that FMR1 is expressed early in development and is silenced between 10 and 12.5 weeks of gestational development (57). In contrast, iPS cells generated from the fibroblasts of FXS patients show that FMR1 remains methylated and transcriptionally silenced in these cell lines (58). Understanding the differences between the human embryonic stem cells and the iPS cells may help unlock key aspects of the methylation and could lead to novel approaches to demethylate the full mutation allele in FXS patients.
FMRP FUNCTION
When FMR1 was cloned in 1991, nothing was known about the function of its protein product, FMRP. Research from the past 20 years has led to the understanding that FMRP plays a critical role in synaptic plasticity. FMRP localizes to the postsynaptic spaces of dendritic spines, where it binds to and represses translation of a targeted subset of dendritic mRNAs. Upon receipt of the appropriate synaptic signals, FMRP derepresses translation, allowing synthesis of key synaptic plasticity proteins to occur at a specific time and location. Despite the progress made to date, only a small number of FMRP's target mRNAs have been verified. Furthermore, the molecular mechanism that FMRP uses to inhibit translation is unclear, and there is only a small amount of evidence for the model of how FMRP is regulated.
FMRP Expression and Functional Protein Domains
FMRP is widely expressed in mammalian tissues (59), but it is especially abundant in the brain and testes (59, 60), consistent with the predominant phenotypes (ID and macroorchidism) observed in patients with FXS. In the brain, FMRP is expressed primarily in neurons, where it is mostly cytoplasmic, being found in the cell body, dendrites, and synapses (59, 61, 62). The pattern of FMRP expression seems to begin early in development and continue throughout life (60). Because of the focus on patients' cognitive deficits, the function of FMRP in nonneuronal cells has received scant attention.
Multiple alternatively spliced isoforms of FMRP exist in humans (45, 63), mice (45), and fruit flies (Figure 3a) the QN domain, is insufficient to properly form short-or long-term memories (64). The corresponding C-terminal region in human FMRP mediates interaction with kinesin and dendritic transport (65), which suggests that it is also important in humans. In mammals, the main isoform of FMRP is a 71-kDa protein composed of several conserved functional domains (Figure 3c ). FMRP has three RNA-binding motifs, including two K homology domains (KH1 and KH2) and the arginine-glycine-glycine (RGG) box. FMRP binds RNAs in a sequence-specific manner mediated by these domains. In particular, the methylation status of the arginines in the RGG box seems to regulate FMRP's affinity for certain RNAs (66). FMRP also contains nuclear localization and export signals (67), which facilitate its shuttling into and out of the nucleus (61). A recent study identified a patient with developmental delay who harbored a novel R138Q mutation in the nuclear localization signal (17) . The functional significance of this mutation is unclear, but it points to the importance of the domain. Although not fully appreciated until recently (see the section titled FMRP Nuclear Function, below), FMRP also contains two tandem Agenet domains at its N terminus (68). The Agenet domains are part of a proposed "royal family" of protein domains that also includes the Tudor, MBT, and Chromo domains (68). The Agenet domains bind trimethylated lysine residues and are structurally similar to the UHFR1 protein, which is believed to interact with methylated histone H3K9 (69). In addition to these conserved domains, other regions of FMRP have also been implicated in protein-protein interactions that are important for its function.
FMRP Nuclear Function
Although FMRP is predominantly cytoplasmic, it can shuttle between the cytoplasm and the nucleus (61). Models of FMRP function suggest that FMRP enters the nucleus to bind its mRNA targets and then chaperone them out of the nucleus (67). For many years, it was believed that export of FMRP from the nucleus www.annualreviews.org • Fragile X SyndromeChromatin immunoprecipitation followed by massively parallel sequencing (ChIP-seq): genomewide method to map DNA/chromatinbinding sites for a given protein was dependent on mRNA synthesis. In support of this idea, a recent report demonstrated that knockdown of the bulk mRNA exporter Tap/NXF1 increased the nuclear localization of FMRP and that FMRP physically associates with Tap/NXF1 in an RNA-dependent manner (70). Also, FMRP associates with the active transcription units of lampbrush chromosomes in amphibian oocytes (70). These new observations offer the first experimental evidence that FMRP binds mRNA in the nucleus, indicating that FMRP may enter the nucleus to bind RNA and facilitate trafficking and/or regulation of its cargo.
FMRP may also have other important functions in the nucleus, according to another recent study (R. Alpatov, U. Wagner, M. 
FMRP Is a Messenger RNA-Binding Protein
FMRP is a selective RNA-binding protein; it binds to as much as 4% of the mRNA in the mammalian brain (71). Microarray and yeast three-hybrid assays have identified more than 400 putative mRNAs that associate with FMRP (72-75), although only 14 of these have been validated by showing direct biochemical interaction ( Table 1) . A recent study used high-throughput sequencing of RNAs isolated through cross-linking immunoprecipitation (HITS-CLIP) to expand the list of possible FMRP target mRNAs (76). The mRNAs identified were significantly enriched for proteins involved in neuronal and synaptic transmission. Strikingly, 28 of the FMRP target genes identified in the new study were candidate genes for autism (76).
There is evidence that FMRP interacts with its target mRNAs through adapter molecules. The most intensely studied putative adapter is brain cytoplasmic 1 (BC1), a small, noncoding RNA. Investigations by Zalfa et al. (77, 78) indicated that BC1 directly binds FMRP and, through base-pairing, interacts with mRNA targets of FMRP. However, this issue is controversial, and a recent report from five labs found no specific BC1/FMRP interactions in vivo or in vitro and showed that the association of FMRP to its target mRNAs does not require BC1 (79). This research suggests that the FMRP/BC1/mRNA interactions previously observed were nonspecific. Furthermore, double-KO mice lacking both FMRP and BC1 showed increased audiogenic seizure susceptibility and more severe place-learning deficits than did single-KO animals lacking only FMRP or BC1 (80). This finding implies that both FMRP and BC1 act in similar neurological pathways but do so independently of one another. In contrast, yet another study found that BC1 increases the affinity of FMRP for one of its protein-binding partners (81), which demonstrates that this issue remains open.
Direct binding of FMRP to its target RNAs is mediated by the presence of RNA secondary structures (Figure 4) , the best studied of which is known as the G quadruplex. A G quadruplex consists of two to four G quartets or tetrads stacked on top of each other; each G quartet is made of four guanines in a planar conformation Other RNA secondary motifs have also been identified in FMRP targets. Multiple U-rich pentamers were found in both coding and 3 UTR regions of some FMRP target mRNAs (89), and a recent study used UV cross-linking and mutagenesis assays to show that FMRP binds to a U-rich region in the 5 UTR of hASH1 (90). The U-rich structure still needs further characterization, and we do not know which domain of FMRP may associate with these U-rich regions. In addition, another secondary structure referred to as the kissing complex has been reported to bind FMRP's KH2 domain in vitro (91). Importantly, the kissing complex was formed by a selection of randomly synthesized RNA, and this structure has not been observed in endogenous mRNA. One explanation may be that the kissing complex forms in vivo only when two RNA molecules interact and, therefore, may be relevant for the association of target mRNAs together with adapter RNAs or microRNAs (miRNAS; see the section titled Mechanisms of Translational Repression, below). Finally, a recent study also showed that FMRP binds to superoxide dismutase 1 (Sod1) mRNA through a novel RNA structure termed Sod1 stem loops interacting with FMRP (SoSLIP) (92). SoSLIP consists of three stem-loop structures separated by short stretches of single-stranded RNA and acts as a translational activator (92). SoSLIP interacts with FMRP's C-terminal region, which includes the RGG box, and competes for binding with the G quadruplex structure (92). 
FMRP Regulates Dendritic Messenger RNAs

FMRP Is a Translational Repressor
In subcellular fractionation experiments, FMRP cosediments with polyribosomes in both neuronal and nonneuronal cells (100-102). FMRP's association with polyribosomes supports the hypothesis that FMRP acts as a translational regulator of its mRNA targets. This association is disrupted by puromycin, which disrupts actively translating polyribosomes, indicating that FMRP is associated with actively translating polyribosomes (102) . In an FXS patient with an I304N missense mutation, FMRP's interaction with actively translating polyribosomes was abolished (100), which indicates that this association is crucial to FMRP's normal function. In addition to interacting with polyribosomes, FMRP is also found in stress granules, which are presumed to sequester mRNAs whose translation is being suppressed, in mRNA-protein (mRNP) complexes (103) . Together, these observations implicate FMRP in dynamic translational regulation of its mRNA partners.
Most evidence is consistent with FMRP inhibiting translation of most of its target mRNAs. FMRP reduces translation of various mRNAs in rabbit reticulocyte lysate, Xenopus laevis oocytes (104), and immortalized cells from an Fmr1 KO mouse (105) . In the reticulocyte assay, removal of the FMRP-binding site from MBP mRNA abolished FMRP's ability to repress its translation, confirming that FMRP binding is necessary for translation regulation (106) . Biochemical and genetic assays also indicate that D. melanogaster dFmr1 represses translation of the Map1B ortholog futsch (51). In vivo assays further demonstrated that the target proteins Map1B, Arc/Arg3.1, and CamKIIα are overexpressed in the brains of Fmr1 KO mice, which is consistent with the loss of FMRP-mediated repression (77, 107). To specifically interrogate FMRP's effect on translation at synapses, synaptoneurosomes from Fmr1 KO mice were examined; they showed increased levels of MAP1B, CamKIIα, and Arc/Arg3.1 proteins (77). Subcellular fractionation of Fmr1 KO synaptoneurosomes also revealed a shift of CamKIIα, PSD-95, and GluR1/2 mRNAs to actively translating polyribosomes, which is consistent with these mRNAs being derepressed (97). Surprisingly, FMRP seems to upregulate the translation of Sod1 mRNA by strengthening SoSLIP's ability to activate translation (92) and to increase translation of hASH1 through an unknown mechanism (90). These findings signify that FMRP may also activate translation of some transcripts. 
Mechanisms of Translational Repression
One model of how FMRP regulates the translation of mRNAs proposes that it inhibits the initiation of translation (Figure 5a) . In (Figure 5b) . This model is supported by data showing that some FMRP cosediments with polyribosomes, even after treatment with puromycin, meaning these polyribosomes probably represent stalled ribosomes (102) . Ribosome runoff experiments in which cells were treated with sodium azide, a nonspecific inhibitor of translation initiation that does not affect elongation, also revealed that a portion of FMRP was associated with stalled ribosomes (108) . These data have been reinforced by a recent HITS-CLIP experiment that suggested that FMRP binds to the coding sequences of mRNA transcripts that are associated with Synaptic plasticity: the ability of synapses to change in strength in response to stimulation; is critical for learning and memory stalled ribosomes (76). Ribosome stalling has not been thoroughly characterized, but it is presumed to be influenced by transfer RNA availability, subcellular localization, folding dynamics of the nascent protein, and RNA secondary structure (109) . Although this hypothesis has not yet been specifically tested, it is reasonable to suppose that FMRP binding to secondary structures in target mRNAs, such as G quadruplexes, may stabilize such structures and act as a steric block for ribosome elongation.
Data also indicate that FMRP represses translation of its target mRNAs through the RNA interference (RNAi) pathway (Figure 5c ). Both D. melanogaster dFmr1 and mammalian FMRP associate with Argonaute 2 and Dicer, critical components of the RNA-induced silencing complex (RISC) (110) (111) (112) , as well as with specific miRNAs (113) . Experiments in D. melanogaster further demonstrated that Argonaute2 is necessary for dFmr1-dependent synaptic plasticity (113) . In vitro, FMRP can help assemble miRNAs on target RNAs, an activity directed by its KH domains (112) . In addition, mouse embryonic fibroblasts (MEFs) from Fmr1 KO mice showed impaired RNAi compared with wild-type MEFs (112), although another study found that FMRP and the RISC associate with different pools of mRNAs and that FMRP-deficient cells have normal RISC activity (103) . Nevertheless, a more recent study showed that FMRP selectively associates with several miRNAs in the mouse brain (114) . Overexpression of two of these miRNAs, miR-125b and miR-132, in cultured rat hippocampal neurons resulted in dendritic spine defects; knockdown of FMRP in these cells rescued both phenotypes (114) . The synaptic mRNA NR2A is also a target of both miR-125b and an FMRP ligand (114) . Similarly, in another study, the 3 UTR of PSD-95 bound both miR-125a and FMRP, and both were required for translation inhibition (115) .
Taken together, these genetic and biochemical data support a mechanism in which FMRP binds to the 3 UTR of target mRNAs, where it then mediates or stabilizes the binding of the complementary miRNA-RISC complex to block translation. Whether the miRNA-RISC/FMRP complex blocks translation initiation or elongation is unknown, and both mechanisms have been implicated for miRNAs in general (116) . Interestingly, one miRNA, miR-125a, shifted from the mRNP fraction into polyribosomes upon activation of synaptoneurosomes with DHPG (115), which is consistent with the miR-125a-RISC/FMRP complex primarily blocking translation initiation prior to activation.
Importantly, these three models of FMRPregulated translation inhibition are not necessarily mutually exclusive, and different mechanisms could apply at different times in the life of an mRNA molecule. For example, FMRP may inhibit translation initiation of its target mRNAs during transport to dendritic spines, but once the mRNAs reach the synapse, FMRP may repress translation via ribosome stalling or recruitment of an miRNA-RISC complex. Likewise, synaptic activation may change the inhibitory mechanism to allow repeated translation starting and stopping. In addition, given that putative binding sites for FMRP are distributed among the 5 UTR, 3 UTR, and protein-coding regions of mRNAs, distinct subsets of mRNA targets may be regulated differently by FMRP on the basis of the relative position of FMRP's binding. For instance, if FMRP binds in the 3 UTR, it may coordinate primarily with miRNAs, but if it binds the 5 UTR or within the gene body, it may form a steric block and cause ribosome stalling. Further work will help unravel these nuances.
Phosphorylation Regulates FMRP-Mediated Translation Inhibition
In vivo, FMRP exists in both phosphorylated and unphosphorylated forms, although phosphorylated FMRP is the predominant form in dendritic granules (117) . FMRP contains a serine residue that is conserved from Drosophila to humans (human Ser500, murine Ser499, Drosophila Ser406) and is the primary phosphorylated residue in FMRP (108 
Long-term depression (LTD):
an activity-dependent decrease in the effectiveness of synaptic transmission that lasts for hours or days AMPAR: α-amino-3-hydroxyl-4-isoxazole propionic acid receptor; its internalization is a key step in hippocampal LTD phosphorylation status of this key serine is believed to control the functionality of FMRP. Although phosphorylation of FMRP does not affect its ability to bind RNA, it does affect its association with polyribosomes and its ability to inhibit translation (108, 115) . Using constitutively phosphorylated and unphosphorylated mimics of murine FMRP containing the S499D and S499A mutations, respectively, Ceman et al. (108) showed that only the S499D-FMRP is still associated with polyribosomes after sodium azide-induced polyribosome runoff. This finding suggests that phosphorylated FMRP is associated with stalled ribosomes, whereas unphosphorylated FMRP allows translation to proceed. This suggestion is consistent with the observation by Mudashetty et al. (115) that overexpression of S499D-FMRP, but not S499A-FMRP, could inhibit translation of a construct containing the 3 UTR of PSD-95. Furthermore, these authors showed that S499D-FMRP shifted this construct into mRNP fractions on sucrose gradients (115) , which argues that the phosphorylation of FMRP suppresses the translation initiation of PSD-95. Interestingly, Dicer associates with unphosphorylated but not phosphorylated FMRP (118) , indicating that phosphorylation of FMRP may also regulate the RNAi pathway by blocking the processing by Dicer of premiRNAs (precursor miRNAs). These data support a model in which phosphorylated FMRP inhibits translation of its target mRNAs while unphosphorylated FMRP allows translation to proceed.
ROLE OF FMRP IN NEUROLOGICAL PATHWAYS
Researchers have put a great deal of effort into elucidating the specific neurological pathways in which FMRP plays a role. Group 1 metabotropic glutamate receptor (mGluR)-dependent long-term depression (mGluR-LTD) has received the most attention, and the details of how FMRP interacts with this pathway are well understood. It is widely believed that the majority of neurological symptoms observed in FXS patients stem from the dysregulation of the mGluR-LTD pathway caused by the absence of FMRP. FMRP is also important in other pathways and other regions of the brain. Much less is known about FMRP's role in these pathways, but it is believed that FMRP acts as a translational repressor in these instances as well. A major focus of the field is determining which pathways are crucial for the symptoms observed in patients and which of these are amenable to pharmaceutical intervention.
mGluR Theory of Fragile X Syndrome
Deficits in synaptic plasticity correlate with learning and memory impairment in the brain, so it was expected that such deficiencies may be at the core of FXS. mGluR-LTD is a major form of synaptic plasticity and depends on the local protein synthesis of postsynaptic, dendritically localized mRNAs in response to synaptic stimulation. This local protein synthesis results in the internalization of α-amino-3-hydroxyl-4-isoxazole propionic acid receptors (AMPAR), a key step in mGluR-LTD. The mGluR theory of FXS proposes that FMRP acts in this pathway downstream of mGluRs and upstream of local protein synthesis. As such, this theory predicts that FMRP represses translation of its mRNA targets in the normal basal state but that upon mGluR activation FMRP repression is released, allowing the burst of local protein synthesis necessary for AMPAR internalization and LTD (Figure 6a) (119) . When FMRP is absent, as in FXS, protein synthesis should be constitutively elevated, which would lead to overactive AMPAR internalization and exaggerated LTD, even in the absence of mGluR activation (Figure 6b) .
In support of this theory, mGluR-LTD is enhanced in the hippocampus of Fmr1 KO mice and does not require new protein synthesis (120, 121) . In addition, dephosphorylation of FMRP following mGluR activation coincides closely with the release of translation inhibition of FMRP target mRNAs, such as PSD-95 (117) . In agreement with this evidence, the levels of several FMRP target mRNAs associated with 35 S] methionine shows that the DHPG-induced synthesis of PSD-95 and CamKIIα proteins observed in wild-type synaptoneurosomes is absent in Fmr1 KO synaptoneurosomes (97). Levels of the FMRP protein itself rise rapidly upon mGluR stimulation (62, 122) and then quickly fall as the protein is ubiquitinated and degraded (122) . Remarkably, blocking this degradation with proteasome inhibitors abolishes mGluR-LTD (122) . Both the persistently enhanced mGluR-LTD and the inability to further increase protein synthesis in response to new synaptic stimuli are the likely culprits behind ID in FXS.
The mGluR theory also predicts that antagonizing the mGluR pathway may lead to a reduction of FXS phenotypes. The mGluR 5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) can indeed rescue behavioral and cognitive deficits in the fruit fly, zebrafish, and mouse models of FXS (123) (124) (125) (126) . MPEP also rescues the altered dendritic spine morphology observed in Fmr1 KO neurons and restores proper AMPAR internalization (127) . Furthermore, genetic reduction of mGluR 5 in Fmr1 KO mice rescues many of the disease-related phenotypes (128, 129 in FXS and has spawned several clinical trials of drugs that target the mGluR pathway.
mGluR-LTD Signaling Pathways: mTOR and ERK
mGluR-LTD requires a cascade of signaling events that culminate in increased protein synthesis and AMPAR internalization. Both mammalian target of rapamycin (mTOR) and extracellular signal-related kinase (ERK) signaling downstream of mGluR activation are required for formation of normal LTD (Figure 7a) . Establishing FMRP's role in these pathways is important for our understanding of FXS and for further development of rational therapeutic interventions. Because the phosphorylation status of FMRP is a key step in the mediation of mGluR-LTD, it makes sense that it would be regulated by the mTOR or ERK pathway. Studies have identified protein phosphatase 2A (PP2A) and ribosomal protein S6 kinase 1 (S6K1) as FMRP's primary phosphatase and kinase, respectively (117, 130) . Within 30 s of mGluR activation, PP2A dephosphorylates FMRP (117) . PP2A activity declines approximately 2 min after stimulation, and by 5 min poststimulation, normal levels of phosphorylated FMRP again become evident (117) . However, it is unclear whether the existing FMRP molecules are rephosphorylated or whether a new pool of phosphorylated FMRP is transported into the dendritic spines. PP2A and S6K1 are controlled by the mTOR pathway. Given the time required for mTOR's activation and the immediate response of PP2A to mGluR stimulation, it is unlikely that mTOR controls the initial activation of PP2A; rather, mTOR is probably only a negative regulator of PP2A. Thus, PP2A may be coupled directly to mGluR receptors or may have another activating mechanism that quickly dephosphorylates FMRP, whereas the mTOR pathway inhibits PP2A and concurrently activates S6K1 to restore FMRP phosphorylation (Figure 7b) .
In addition to mTOR regulating FMRP phosphorylation, recent evidence indicates that the mTOR pathway is also negatively regulated by FMRP, which places mTOR downstream as well as upstream of FMRP. Consequently, Fmr1 KO mice show a general exaggeration of mTOR signaling, including increased association of raptor with mTOR, higher levels of mTOR kinase activity, increased phosphorylation of the mTOR targets S6 kinase and 4E-BP, and elevated levels of the eIF4F complex (131) . Phosphatidylinositol 3-kinase (PI3K) plays a key role in activating the mTOR pathway (Figure 7a) ; PI3K's catalytic subunit p110β and its upstream activator PIKE are putative targets of FMRP, and both are upregulated in Fmr1 KO mice (131) . Interestingly, the PI3K inhibitor LY294002 reduces levels of phosphorylated mTOR in Fmr1 KO mice to wild-type levels (131) . These results suggest that FMRP normally downregulates the mTOR pathway by repressing PIKE and PI3K and that, in the absence of FMRP, mTOR signaling is at or near saturation and therefore insensitive to mGluR activation.
They also imply that FMRP controls its own regulation by derepressing mTOR, thereby allowing mTOR to phosphorylate FMRP.
Further work has shown that FMRP regulates PI3K activity by controlling the synthesis and synaptic localization of p110β (132) . Treatment of cortical synaptoneurosomes from Fmr1 KO mice with LY294002 reversed the phenotypes of increased protein synthesis, AMPAR internalization, and spine density normally observed in Fmr1 KO neurons (132) . In contrast, treatment with the ERK1/2 antagonist U0126 showed no effect on the dysregulated protein synthesis found in FMRP-deficient neurons (132) . These results suggest that PI3K inhibitors may hold promise as FXS therapeutics.
In disagreement with the above results, however, a recent study found that increased protein synthesis in hippocampal slices from Fmr1 KO mice is rescued by inhibition of ERK1/2, but not by inhibition of mTOR (133) . This study revealed that the ERK pathway is not upregulated in Fmr1 KO neurons (133) , which suggests that in the absence of FMRP, the process of local protein synthesis is hypersensitive to normal levels of ERK signaling. Another report found that mGluR stimulation of Fmr1 KO synaptoneurosomes results in dephosphorylation of ERK, whereas in wild-type synaptoneurosomes, ERK remains phosphorylated (134) . Although some differences in tissue preparation between studies may have partly contributed to the divergent results, it is not clear how the different findings concerning the mTOR and ERK pathways will be reconciled.
OTHER mGluR SYNAPTIC PLASTICITY
Early studies were unable to identify any disruptions in hippocampal long-term potentiation (LTP) in Fmr1 KO mice (135, 136) . Recently, though, a new method of inducing LTP by bath application of glycine showed that this form of LTP was reduced in Fmr1 KO hippocampal tissue slices (137) . Furthermore, in wild-type mice, the group 1 mGluR
Long-term potentiation (LTP):
an activity-dependent increase in the effectiveness of synaptic transmission that lasts for hours or days antagonist DL-AP3 and the NMDA receptor antagonist AP5 independently blocked this glycine-induced LTP (137) . However, application of AP5 did not further decrease glycine-induced LTP in Fmr1 KO mice, whereas application of DL-AP3 resulted in a slight decrease (137) . These results suggest that glycine-induced LTP is mediated by both NMDA receptors and group 1 mGluRs, but that FMRP only plays a role in mGluR-LTP.
Much of the research into the function of FMRP has focused on its role in the hippocampus, but additional evidence shows that FMRP affects mGluR synaptic plasticity in other areas of the brain as well. The emotional symptoms observed in FXS patients point to possible involvement of the amygdala. Consistent with evidence from the hippocampus, there is a reduction of AMPAR surface expression in the amygdalas of Fmr1 KO mice (138) . Interestingly, although this phenomenon leads to increased mGluR-LTD in the hippocampus, it causes impaired mGluR-LTP in the amygdala (138) . A reduction in miniature excitatory synaptic current frequency was also observed, which indicates possible presynaptic defects (138) . Treatment with MPEP does not rescue either the mGluR-LTP deficiencies or the reduction in surface AMPARs in the amygdalas of Fmr1 KO mice; however, it does reverse the changes observed in presynaptic release, suggesting that some symptoms associated with the amygdala may be amenable to pharmacological intervention (138) .
The anterior cingulate cortex (ACC) is also involved in learning and memory. Stimulation of group 1 mGluRs in the ACC with DHPG upregulates the expression of FMRP via Ca 2+ -dependent signaling pathways (139) . Such upregulation is absent in Ca 2+ /calmodulinstimulated adenylate cyclase 1 (AC1) KO mice as well as in calcium/calmodulin-dependent kinase IV (CaMKIV) KO mice (139, 140) , indicating that AC1 and CaMKIV mediate the regulation of FMRP by group 1 mGluRs in the ACC. The increase in FMRP is abolished by actinomycin D (139), a transcription inhibitor, which suggests that this regulation occurs at the transcriptional level.
Alternate Neurological Pathways
In addition to mGluR synaptic plasticity, FMRP also affects dopaminergic and GABAergic brain function. Dopamine (DA) plays a major role in neurological pathways active in the prefrontal cortex. DA can bind to five different G protein-coupled receptors (GRKs), named D1-D5. Upon activation of the D1 receptors, prefrontal cortex neurons normally exhibit an increase in surface expression and phosphorylation of AMPARs, but such increases are absent in neurons from Fmr1 KO mice (141, 142) . FMRP-deficient neurons also show impairment of DA-dependent LTP (141) . Treatment of Fmr1 KO mice with a D1 receptor agonist partially reduced their hyperactivity and improved their motor function (141) , which may represent another potential avenue of treatment for FXS patients.
Finally, GABA A synaptic transmission is impaired in models of FXS. GABA A receptors are the major inhibitory receptors in the brain and have been implicated in learning and memory. These findings have motivated research into the possible role of GABAergic dysregulation in FXS. Indeed, the mRNA for the δ subunit of the GABA A receptor is a ligand of FMRP (143); it and several other subunits of GABA A are reduced in the brains of Fmr1 KO mice (143, 144) . Remarkably, all three subunits of the invertebrate GABA receptor are underexpressed in a D. melanogaster model of FXS (143) . Neurophysiological experiments in brain slices provided direct evidence of abnormal GABA transmission in KO mice (145, 146) . These data clearly suggest that GABA A agonists could be effective in treating FXS. In fact, the aforementioned D. melanogaster-based screen uncovered three compounds involved in GABAergic signaling, including GABA itself, that rescued the dFmr1 KO phenotype (55). GABA A agonists are some of the most promising compounds for FXS currently used in clinical trials.
CONCLUSION AND FUTURE DIRECTIONS
The year 2011 marks the twentieth anniversary of the cloning of FMR1. Since then, tremendous progress has been made in our understanding of FMRP's normal function and how its absence leads to the symptoms observed in FXS patients. Most research has focused on FMRP's function as a translational repressor in hippocampal mGluR-LTD. The resulting mGluR theory of FXS is supported by a great deal of evidence and can account for many of the neurological symptoms observed in patients.
Despite these advances, many lines of inquiry remain open. Animal models coupled with pharmacological assays may allow investigators to correlate specific FXS phenotypes with the dysregulation of specific target mRNAs. Also, there are conflicting data concerning FMRP's mechanism of translation repression. It may directly interact with its target mRNAs, or it may rely on adapter molecules such as BC1. Recent evidence has reinforced the idea that FMRP acts through the miRNA pathway, but the possibility remains that it may inhibit translation initiation or elongation through more direct means.
A major goal of FXS research has been the development of therapies to improve the quality of life of those who suffer from FXS. This goal may soon be within reach, as investigations into the function of FMRP have identified several promising pharmacological agents, including mGluR antagonists, PI3K inhibitors, and GABAergic signaling agonists. Clinical trials have already begun to assess the efficacy of some of these compounds in humans (147, 148) . Although these trials have not yet been completed, there is now justifiable optimism that an effective treatment for FXS may finally be on the horizon.
SUMMARY POINTS
1. FXS is a very common form of inherited ID. FXS patients often display symptoms of autism.
2. FXS is caused by a large expansion of the CGG repeat in the 5 UTR of FMR1, which causes methylation and silencing of FMR1 and the lack of FMRP.
3. FMRP is a selective mRNA-binding protein that represses translation of a subset of dendritically localized mRNAs. FMRP derepresses translation in response to synaptic activation.
4. FMRP plays a critical role in dendritic local protein synthesis and synaptic plasticity. In its absence, mGluR-LTD signaling is overactive, and synaptic plasticity is reduced. This molecular dysregulation is the major cause of the cognitive deficits observed in FXS patients.
5. The phosphorylation status of FMRP regulates its function. Phosphorylated FMRP represses translation of its target mRNAs, and unphosphorylated FMRP allows translation to proceed.
6. FMRP may inhibit translation by blocking initiation of translation, causing ribosome stalling, interacting with the RNAi pathway, or a combination of the three. 
